ABT Stock Cash Flow Statements

Abbott Laboratories Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Abbott Laboratories Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30	2011-06-30	2011-03-31	2010-09-30	2010-06-30	2010-03-31

cash flow from (used in) operating activities:
net earnings	1,779,000,000	1,325,000,000	9,229,000,000	1,646,000,000	1,302,000,000	1,225,000,000	1,594,000,000	1,436,000,000	1,375,000,000	1,318,000,000	1,033,000,000	1,435,000,000	2,018,000,000	2,447,000,000	1,989,000,000	2,100,000,000	1,189,000,000	1,793,000,000	2,162,000,000	1,232,000,000	537,000,000	564,000,000	1,049,000,000	960,000,000	1,006,000,000	672,000,000	563,000,000	733,000,000	418,000,000	603,000,000	283,000,000	419,000,000	-329,000,000	615,000,000	316,000,000	580,000,000	784,000,000	2,292,000,000	539,000,000	466,000,000	375,000,000	965,733,000	476,055,000	544,661,000	1,942,803,000	1,724,612,000	1,242,124,000	303,181,000	1,942,782,000	863,818,000	890,660,000	1,291,650,000	1,003,015,000
adjustments to reconcile net earnings to net cash from operating activities —
depreciation	357,000,000	336,000,000	342,000,000	331,000,000	334,000,000	333,000,000	332,000,000	328,000,000	302,000,000	315,000,000	311,000,000	317,000,000	315,000,000	311,000,000	369,000,000	327,000,000	370,000,000	425,000,000	358,000,000	298,000,000	272,000,000	267,000,000	273,000,000	270,000,000	268,000,000	267,000,000	269,000,000	288,000,000	268,000,000	255,000,000	256,000,000	252,000,000	200,000,000	202,000,000	203,000,000	232,000,000	201,000,000	215,000,000	226,000,000	239,000,000	224,000,000	239,939,000	238,938,000	221,431,000	430,344,000	320,886,000	354,211,000	420,712,000	379,366,000	354,120,000	313,158,000	303,812,000	287,249,000
amortization of intangible assets	420,000,000	420,000,000	465,000,000	470,000,000	471,000,000	472,000,000	481,000,000	496,000,000	498,000,000	491,000,000	496,000,000	498,000,000	507,000,000	512,000,000	514,000,000	520,000,000	504,000,000	509,000,000	508,000,000	510,000,000	553,000,000	561,000,000	483,000,000	484,000,000	483,000,000	486,000,000	544,000,000	562,000,000	584,000,000	501,000,000	392,000,000	522,000,000	140,000,000	145,000,000	144,000,000																363,866,000
share-based compensation	142,000,000	289,000,000	111,000,000	117,000,000	141,000,000	304,000,000	114,000,000	117,000,000	132,000,000	281,000,000	115,000,000	123,000,000	142,000,000	305,000,000	106,000,000	114,000,000	132,000,000	288,000,000	98,000,000	100,000,000	115,000,000	233,000,000	85,000,000	94,000,000	114,000,000	226,000,000	83,000,000	101,000,000	212,000,000	75,000,000	92,000,000	171,000,000	49,000,000	62,000,000	152,000,000	44,000,000	57,000,000	148,000,000	40,000,000	49,000,000	119,000,000	44,758,000	51,548,000	125,746,000	75,608,000	85,785,000	197,342,000	67,838,000	76,457,000	175,808,000	72,146,000	84,224,000	173,866,000
trade receivables	-410,000,000	-262,000,000	-158,000,000	-57,000,000	-325,000,000	-151,000,000	68,000,000	-461,000,000	-196,000,000	233,000,000	341,000,000	530,000,000	-188,000,000	-751,000,000	-189,000,000	-394,000,000	35,000,000	165,000,000	-581,000,000	-470,000,000	231,000,000	-104,000,000	82,000,000	-22,000,000								30,000,000									82,000,000				-54,220,000	611,030,000	132,482,000	-243,358,000	216,935,000	298,953,000	230,374,000	-45,803,000	291,638,000
inventories	3,000,000	-255,000,000	235,000,000	220,000,000	-103,000,000	-410,000,000	295,000,000	140,000,000	-248,000,000	-419,000,000	-189,000,000	-194,000,000	-476,000,000	-554,000,000	15,000,000	71,000,000	-5,000,000	-537,000,000	345,000,000	149,000,000	-550,000,000	-437,000,000	137,000,000	-190,000,000																								-2,458,000	5,195,000	44,784,000
other	-244,000,000	-436,000,000	639,000,000	-22,000,000	140,000,000	-748,000,000	1,937,000,000	-179,000,000	-660,000,000	-1,076,000,000	64,000,000	71,000,000	92,000,000	-205,000,000	166,000,000	-37,000,000	-97,000,000	-6,000,000	-23,000,000	247,000,000	164,000,000	-369,000,000	550,000,000	352,000,000	-890,000,000	15,000,000	578,000,000	-12,000,000	42,000,000	512,000,000	-51,000,000	101,000,000	6,000,000			234,000,000	71,000,000	230,000,000	45,000,000	0	27,000,000				-10,310,000	1,159,000	11,149,000	1,138,458,000	4,566,000	7,804,000
net cash from operating activities	2,047,000,000	1,417,000,000	2,868,000,000	2,705,000,000	1,960,000,000	1,025,000,000	3,038,000,000	1,877,000,000	1,203,000,000	1,143,000,000	2,326,000,000	2,780,000,000	2,410,000,000	2,065,000,000	3,067,000,000	2,701,000,000	2,128,000,000	2,637,000,000	3,798,000,000	2,066,000,000	1,322,000,000	715,000,000	2,416,000,000	1,948,000,000	1,060,000,000	712,000,000	2,183,000,000	1,244,000,000	1,108,000,000	2,005,000,000	1,351,000,000	574,000,000	1,217,000,000			1,195,000,000	941,000,000	2,000,000	1,201,000,000	900,000,000	336,000,000	522,125,000	716,559,000	460,255,000	3,519,502,000	2,066,829,000	2,224,930,000	3,054,430,000	2,503,152,000	2,011,146,000	2,548,413,000	2,348,297,000	1,522,752,000
capex	-502,000,000	-484,000,000	-720,000,000	-556,000,000	-533,000,000	-398,000,000	-755,000,000	-560,000,000	-507,000,000	-380,000,000	-610,000,000	-467,000,000	-379,000,000	-321,000,000	-614,000,000	-461,000,000	-413,000,000	-397,000,000	-679,000,000	-496,000,000	-642,000,000	-360,000,000	-434,000,000	-401,000,000	0	0	0	0	0	0	0	0	0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
free cash flows	1,545,000,000	933,000,000	2,148,000,000	2,149,000,000	1,427,000,000	627,000,000	2,283,000,000	1,317,000,000	696,000,000	763,000,000	1,716,000,000	2,313,000,000	2,031,000,000	1,744,000,000	2,453,000,000	2,240,000,000	1,715,000,000	2,240,000,000	3,119,000,000	1,570,000,000	680,000,000	355,000,000	1,982,000,000	1,547,000,000	1,060,000,000	712,000,000	2,183,000,000	1,244,000,000	1,108,000,000	2,005,000,000	1,351,000,000	574,000,000	1,217,000,000			1,195,000,000	941,000,000	2,000,000	1,201,000,000	900,000,000	336,000,000	522,125,000	716,559,000	460,255,000	3,519,502,000	2,066,829,000	2,224,930,000	3,054,430,000	2,503,152,000	2,011,146,000	2,548,413,000	2,348,297,000	1,522,752,000
cash flow from (used in) investing activities:
acquisitions of property and equipment	-502,000,000	-484,000,000	-720,000,000	-556,000,000	-533,000,000	-398,000,000	-755,000,000	-560,000,000	-507,000,000	-380,000,000	-610,000,000	-467,000,000	-379,000,000	-321,000,000	-614,000,000	-461,000,000	-413,000,000	-397,000,000	-679,000,000	-496,000,000	-642,000,000	-360,000,000	-434,000,000	-401,000,000
acquisitions of businesses and technologies, net of cash acquired							0	-51,000,000							0	-172,000,000	0	-15,000,000	-10,000,000	0			1,000,000	-11,000,000
proceeds from business dispositions			0	0			0	0			0	0			0	86,000,000			10,000,000	0			0	0			0			-29,000,000
sales (purchases) of other investment securities	-52,000,000	8,000,000		-40,000,000	77,000,000	-28,000,000		-38,000,000	79,000,000	-86,000,000		-21,000,000	59,000,000	-41,000,000		-108,000,000	95,000,000	-14,000,000		17,000,000	4,000,000	-36,000,000		-24,000,000	0	2,000,000
net cash from investing activities	-582,000,000	-470,000,000	-866,000,000	-594,000,000	-453,000,000	-425,000,000	-824,000,000	-634,000,000	-1,213,000,000	-462,000,000	-632,000,000	-484,000,000																							226,000,000
cash flow from (used in) financing activities:
net borrowings (repayments) of short-term debt and other	-16,000,000	-36,000,000		44,000,000	-43,000,000	-127,000,000		-61,000,000	13,000,000	-42,000,000		24,000,000	5,000,000	8,000,000		-27,000,000	-4,000,000	24,000,000		-28,000,000	-20,000,000	51,000,000		12,000,000	27,000,000	13,000,000	-118,000,000
proceeds from issuance of long-term debt	2,000,000	1,000,000		1,000,000				0				1,000,000								1,000,000																															0
repayments of long-term debt	-1,000,000	-1,001,000,000		-2,000,000				-1,445,000,000				-1,000,000	-1,000,000	-751,000,000		-40,000,000	-3,000,000	-2,000,000		-1,330,000,000	-1,000,000	-1,000,000		-2,000,000
purchases of common shares	-6,000,000	-280,000,000	-315,000,000	-751,000,000	-3,000,000	-226,000,000	-259,000,000	-2,000,000	-426,000,000	-540,000,000	-685,000,000	-798,000,000	-5,000,000	-2,307,000,000	-974,000,000	-579,000,000	-471,000,000	-275,000,000	-161,000,000	-2,000,000	-4,000,000	-236,000,000	-496,000,000	-1,000,000
proceeds from stock options exercised	35,000,000	287,000,000	25,000,000	92,000,000	13,000,000	134,000,000	34,000,000	56,000,000	15,000,000	62,000,000	41,000,000	57,000,000	10,000,000	59,000,000	82,000,000	70,000,000	17,000,000	86,000,000	16,000,000	83,000,000	57,000,000	89,000,000	7,000,000	47,000,000	117,000,000	127,000,000	74,000,000	33,000,000	137,000,000	89,000,000	57,000,000	129,000,000
dividends paid	-1,029,000,000	-1,026,000,000	-958,000,000	-960,000,000	-961,000,000	-957,000,000	-888,000,000	-888,000,000	-890,000,000	-890,000,000	-823,000,000	-826,000,000	-828,000,000	-832,000,000	-798,000,000	-801,000,000	-803,000,000	-800,000,000	-641,000,000	-639,000,000	-642,000,000	-638,000,000	-568,000,000	-569,000,000
net cash from financing activities	-1,097,000,000	-2,055,000,000	-1,861,000,000	-1,576,000,000	-791,000,000	-1,176,000,000	-2,052,000,000	-2,340,000,000	-1,289,000,000	-1,410,000,000	-1,457,000,000	-1,543,000,000																																		115,367,000	286,074,000
effect of exchange rate changes on cash and cash equivalents	51,000,000	24,000,000	-83,000,000	36,000,000	-13,000,000	-36,000,000	25,000,000	-29,000,000	-27,000,000	8,000,000	51,000,000	-96,000,000	-71,000,000	-6,000,000	-13,000,000	-29,000,000	4,000,000	-32,000,000	78,000,000	38,000,000	25,000,000	-70,000,000	27,000,000	-49,000,000	2,000,000	4,000,000			35,000,000	24,000,000	8,000,000	65,000,000															34,700,000		14,298,000	66,203,000
net increase in cash and cash equivalents	419,000,000	-1,084,000,000	58,000,000	571,000,000	703,000,000	-612,000,000	187,000,000	-1,126,000,000	-1,326,000,000	-721,000,000	288,000,000	657,000,000	1,262,000,000	-2,124,000,000	497,000,000	644,000,000	604,000,000	1,216,000,000	2,358,000,000	-283,000,000			-231,000,000																43,000,000						944,172,000			972,281,000
cash and cash equivalents, beginning of year	0	7,616,000,000	0	0	0	6,896,000,000	0	0	0	9,882,000,000	0	0	0	9,799,000,000	0	0	0	6,838,000,000	0	0	0	3,860,000,000	0	0	0	3,844,000,000	0	0	9,407,000,000	0	0	18,620,000,000	0	0	5,001,000,000	0	0	4,063,000,000	0	0	3,475,000,000	0	0	10,802,163,000	0	0	6,812,820,000	0	0	3,648,371,000	0	0	8,809,339,000
cash and cash equivalents, end of period	419,000,000	6,532,000,000		571,000,000	703,000,000	6,284,000,000		-1,126,000,000	-1,326,000,000	9,161,000,000		657,000,000	1,262,000,000	7,675,000,000		644,000,000	604,000,000	8,054,000,000		-283,000,000	1,386,000,000	3,377,000,000		954,000,000	115,000,000	3,022,000,000	4,304,000,000	-792,000,000	3,857,000,000	1,337,000,000	969,000,000	8,706,000,000	-78,000,000	-756,000,000	3,334,000,000	-916,000,000	822,000,000	3,226,000,000	43,000,000	1,510,000,000	2,060,000,000	-2,689,800,000	1,199,134,000	4,373,120,000	944,172,000	2,706,866,000	4,345,910,000	972,281,000	1,336,862,000	2,740,156,000	-503,557,000	2,754,882,000	1,566,820,000
adjustments to reconcile earnings to net cash from operating activities —
investing and financing losses
prepaid expenses and other assets
trade accounts payable and other liabilities
income taxes
purchases of investment securities
proceeds from sales of investment securities																																																					874,139,000
proceeds from issuance of (repayments of) short-term debt, net and other
proceeds from issuance of long-term debt and debt with maturities over 3 months
repayments of long-term debt and debt with maturities over 3 months
cash and cash equivalents, end of year
supplemental cash flow information:
income taxes paid
interest paid

net cash (used in) investing activities														-360,000,000		-651,000,000	-264,000,000	-422,000,000		-472,000,000	-619,000,000	-393,000,000		-432,000,000
net cash (used in) financing activities														-3,823,000,000		-1,377,000,000	-1,264,000,000	-967,000,000		-1,915,000,000	658,000,000	-735,000,000		-513,000,000
loss on extinguishment of debt
adjustments to reconcile net earnings to net cash from operating activities-
adjustments to reconcile earnings to net cash from operating activities -
amortization of inventory step-up																											0	0	32,000,000	18,000,000	430,000,000	392,000,000
adjustments to reconcile net earnings to net cash from operating activities -
net decrease in cash and cash equivalents																						-483,000,000
amortization of bridge financing fees
gains on sale of businesses
gain on sale of mylan n.v. shares
proceeds from the sale of mylan n.v. shares																														53,000,000	239,000,000	1,685,000,000
purchase of alere preferred stock
acquisition and contingent consideration payments related to business acquisitions
gain on sale of businesses
payment of debt issuance costs
payment of contingent consideration
proceeds from business disposition																																5,472,000,000	0	0	25,000,000	0	0	230,000,000
sales (purchases) of investment securities																																			446,000,000				2,239,000,000
net proceeds (repayments of) short-term debt and other																													6,000,000
impact of currency devaluation																																	4,000,000	0	477,000,000
mylan n.v. equity investment adjustment
net (repayments of) short-term debt and other
gain on sale of discontinued operations
net (repayments of) proceeds from issuance of short-term debt and other
proceeds from the issuance of long-term debt																																				0	0	2,485,000,000
proceeds from stock options exercised, including income tax benefit																																	76,000,000	43,000,000	87,000,000	50,000,000	57,000,000	156,000,000	64,000,000	56,000,000	170,000,000	37,656,000	73,641,000	68,963,000	524,093,000	359,039,000	687,279,000	47,808,000	93,903,000	175,752,000			188,169,000
gain on sale of mylan shares
proceeds from the sale of mylan shares
net cash (used in) from investing activities
net cash (used in) from operating activities
amortization of intangibles																																				151,000,000	151,000,000	156,000,000	129,000,000	161,000,000	174,000,000	196,753,000	196,892,000	199,422,000	329,384,000	370,549,000	389,056,000	417,674,000	432,046,000	391,547,000			275,252,000
(purchases) sales of other investment securities
net (repayments of ) proceeds from issuance of short-term debt and other
contingent and other consideration payments related to business acquisitions
net (repayments of) proceeds from short-term debt and other
acquisitions of business and technology
proceeds from issuance of short-term debt and other																																							397,000,000	-341,000,000	1,213,000,000	374,281,000	901,226,000	2,248,631,000		1,297,740,000	1,399,029,000			396,213,000			775,006,000
transfer of cash and cash equivalents to abbvie inc.
acquired in-process and collaborations research and development																																													0	110,000,000	150,000,000
acquisitions of businesses and technology
payment of long-term debt
contingent consideration payment related to a business acquisition
net cash (used in) from financing activities
acquisition of businesses and technology
release of restricted funds
proceeds from issuance of (repayments of) short-term debt and other
acquired in-process research and development																																																0	172,500,000	100,000,000
(purchases of) proceeds from sales of investment securities
release of (deposit of) restricted funds																																																0
repayments of short-term debt and other
acquisitions of businesses, net of cash acquired
deposit of restricted funds
net (decrease) in cash and cash equivalents
derecognition of a contingent liability associated with the conclusion of the tap pharmaceutical products inc. joint venture
proceeds from sales of (purchases of) investment securities																																																			14,317,000
(repayments of) proceeds from issuance of short-term debt and other
payments of long-term debt
proceeds from stock options exercised, including tax benefit																																																			68,457,000

We provide you with 20 years of cash flow statements for Abbott Laboratories stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Abbott Laboratories stock. Explore the full financial landscape of Abbott Laboratories stock with our expertly curated income statements.

The information provided in this report about Abbott Laboratories stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.